To evaluate the relevance of visual rating scales for assessing brain atrophy in structural MRI amidst the rise of automated volumetric assessment tools, highlighting their clinical significance.
Key Findings:
Visual rating scales face limitations such as inter-rater variability and low sensitivity in early disease stages, which can impact diagnostic accuracy.
Automated volumetric assessment tools have shown superiority in controlled studies but lack validation in routine clinical practice, raising questions about their practical utility.
The ASS demonstrates strong reliability and correlates well with automated volumetric measures, indicating potential clinical utility, especially in settings with limited resources.
Interpretation:
While automated tools are advancing, visual rating scales like the ASS remain relevant and necessary for clinical practice, particularly in settings lacking advanced imaging capabilities.
Limitations:
Automated methods have not been validated in diverse clinical settings, limiting their applicability.
MRI volumetry is sensitive to scanner types and acquisition sequences, complicating standardization and potentially affecting diagnostic outcomes.
Current guidelines still favor visual assessments due to the lack of widespread clinical validation for automated tools, emphasizing the need for further research.
Conclusion:
The ASS could enhance the visual differentiation of neurodegenerative diseases and warrants further validation against clinical data, particularly in diverse patient populations.
